23 October 2019 - - US-based Abzena has appointed Kimball Hall as chief operating officer, adding to the company's executive leadership team, the company said.

Hall will focus on the growth of Abzena as the leading Partner Research Organization for outsourced integrated gene to GMP services for large molecules and antibody drug conjugates.

She joins Abzena from Genentech, a member of the Roche Group, a Swiss biopharmaceutical company.

Hall served for four years at Genetech as SVP and Global Head of Drug Substance, as well as a member of the Genentech executive committee, with responsibility for seven internal sites and 4,300 people covering both biologics and small molecules.

Hall was also responsible for 27 external manufacturing locations. Her accomplishments included ensuring a strong Quality and Safety Culture, supporting 5 new commercial product launches, and establishing small volume production.

Before joining Genentech, Hall served for 16 years at Amgen in multiple roles of increasing responsibility, culminating as VP of manufacturing.
Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry.

The company maintains resources around the world, with facilities in the US and UK. Abzena is partnered with Welsh, Carson, Anderson and Stowe, one of the world's leading private equity investors.